CD19 and bacterial infectious disease: Prevention of serious bacterial infections in patients with hypogammaglobulinemia after CD19-redirected CAR-T therapy and also in patients with primary immunodeficiency (PID) who suffer from impaired immune systems can be achieved through immunoglobulin replacement (14, 15, 155–158).